Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Bayarmagnai Weinstein, Bogdan Muresan, Sara Solano, Antonio Vaz de Macedo, YoonJung Lee, Yu-Chen Su, Yeseul Ahn, Gabriela Henriquez, Christina Carmago, Gwang-Jin Kim, David O. Carpenter

Open source

DOI: 10.24926/iip.v12i4.4345
Published: 2021-11-19
Container: INNOVATIONS in pharmacy
Publisher: University of Minnesota
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.24926/iip.v12i4.4345,
  title = {Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review},
  author = {Bayarmagnai Weinstein and Bogdan Muresan and Sara Solano and Antonio Vaz de Macedo and YoonJung Lee and Yu-Chen Su and Yeseul Ahn and Gabriela Henriquez and Christina Carmago and Gwang-Jin Kim and David O. Carpenter},
  year = {2021},
  journal = {INNOVATIONS in pharmacy},
  doi = {10.24926/iip.v12i4.4345},
  url = {https://doi.org/10.24926/iip.v12i4.4345}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review
AU  - Bayarmagnai Weinstein
AU  - Bogdan Muresan
AU  - Sara Solano
AU  - Antonio Vaz de Macedo
AU  - YoonJung Lee
AU  - Yu-Chen Su
AU  - Yeseul Ahn
AU  - Gabriela Henriquez
AU  - Christina Carmago
AU  - Gwang-Jin Kim
AU  - David O. Carpenter
PY  - 2021
JO  - INNOVATIONS in pharmacy
DO  - 10.24926/iip.v12i4.4345
UR  - https://doi.org/10.24926/iip.v12i4.4345
ER  -

APA

Weinstein, B., Muresan, B., Solano, S., Macedo, A. V. D., Lee, Y., Su, Y., Ahn, Y., Henriquez, G., Carmago, C., Kim, G., & Carpenter, D. O. (2021). Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review. INNOVATIONS in pharmacy. https://doi.org/10.24926/iip.v12i4.4345

Source records

crossref · retrieved 2026-09-25T19:54:49.715Z